Genentech, Inc.
NEWS
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
A look at the latest batch of FDA approvals this year.
A look at what three ex-Genentech employees have accomplished at Denali so far.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.
One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.
JOBS
IN THE PRESS